ChemoCentryx Expands Partnership With Vifor Pharma, Licenses CCX140 For Renal Diseases

ChemoCentryx Inc CCXI has expanded its kidney health partnership with Vifor Pharma to include the development and commercialization of CCX140 for renal diseases.

CCX140 has previously completed a successful Phase II clinical trial in patients with diabetic kidney disease.

Global Markets

Under the deal, ChemoCentryx will retain commercialization rights of CCX140 in the United States and China, while Vifor Pharma gains rights in all other markets.

In addition, Vifor Pharma receives an option to develop and commercialize CCX140 in chronic kidney disease (CKD) with U.S. co-promotion rights retained by ChemoCentryx.

As part of the deal, ChemoCentryx will receive an upfront cash payment of $50 million along with certain milestone payments and sales royalties.

In May 2016, ChemoCentryx granted license to Vifor Pharma to commercialize CCX168 (international nonproprietary name: avacopan) in Europe, Canada, Mexico, Central and South America and South Korea. Avacopan is being studied for the treatment of orphan and rare renal diseases.

At last check, shares of ChemoCentryx were up 2.74 percent at $8.24.